OJBD  Vol.3 No.4 , December 2013
Splenic Marginal Zone Lymphoma in a Patient with Positive Hepatitis B Virus Serology*
Abstract: We present a case in which an elderly woman diagnosed with a splenic marginal zone lymphoma (MZL) was found to have positive Hepatitis B serology. Link with Hepatitis C virus is well documented but reports of association of Hepatitis B virus (HBV) with splenic marginal zone lymphoma are still emerging. A 69-year-old lady presented with weight loss, pancytopenia and marked splenomegaly. Prior to commencing treatment, Hepatitis B serology confirmed Hepatitis B infection. She was treated with Chlorambucil along with anti-hepatitis B prophylaxis and HBV PCR monitoring. She had an excellent response to treatment with resolution of symptoms and splenomegaly. This case highlights the importance of testing for hepatitis B serology in patients diagnosed with splenic MZLs as causative agent. Although the association between HCV is well documented in the literature, a relationship between HBV may also be important. Also, chemotherapy +/- Rituximab for splenic MZL is associated with the reactivation of latent infections; hence providing prophylactic cover for pre-existing latent HBV infection may be required to prevent reactivation as in this case.
Cite this paper: Q. Iman, E. Dewi and B. Syed, "Splenic Marginal Zone Lymphoma in a Patient with Positive Hepatitis B Virus Serology*," Open Journal of Blood Diseases, Vol. 3 No. 4, 2013, pp. 105-107. doi: 10.4236/ojbd.2013.34021.

[1]   C. Thieblemont, F. Davi, M. E. Noguera, J. Brière, F. Bertoni, E. Zucca, et al., “Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions,” Oncology (Williston Park), Vol. 26, No. 2, 2012, pp. 194-202.

[2]   M. Mollejo, F. I. Camacho, P. Algara, E. Ruiz-Ballesteros, J. F. García and M. A. Piris, “Nodal and Splenic Marginal Zone B Cell Lymphomas,” Hematological Oncology, Vol. 23, No. 3-4, 2005, pp. 108-118.

[3]   L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, et al., “Integruppo Italiano Linfomi; Splenic Marginal Zone Lymphoma: A Prognostic Model for Clinical Use,” Blood, Vol. 107, No. 12, 2006, pp. 4643-4649.

[4]   C. Montalbán, V. Abraira, L. Arcaini, E. Domingo-Do- menech, P. Guisado-Vasco, E. Iannito, et al., “Splenic Marginal Zone Lymphoma Study Group. Risk Stratification for Splenic Marginal Zone Lymphoma Based on Haemoglobin Concentration, Platelet Count, High Lactate Dehydrogenase Level and Extrahilar Lymphadenopathy: Development and Validation on 593 Cases,” British Journal of Haematology, Vol. 159, No. 2, 2012, pp. 164-171.

[5]   J. Peveling-Oberhag, G. Crisman, A. Schmidt, C. Doring, M. Lucioni, L. Arcaini, et al., “Dysregulation of Global MicroRNA Expression in Splenic Marginal Zone Lymphoma and Influence of Chronic Hepatitis C Virus Infection,” Leukemia, Vol. 26, No. 7, 2012, pp. 1654-1662.

[6]   S. S. Chuang, Y. L. Liao, S. T. Chang, Y. C. Hsieh, S. Y. Kuo, C. L. Lu, et al., “Hepatitis C Virus Infection Is Sig- nificantly Associated with Malignant Lymphoma in Taiwan, Particularly with Nodal and Splenic Marginal Zone Lymphomas,” Journal of Clinical Pathology, Vol. 63, No. 7, 2010, pp. 595-598.

[7]   B. Szynglarewicz, R. Matkowski, Z. Smorag, J. Forgacz, M. Pudelko and J. Kornafel, “Hepatitis C Virus Infection and Locally Advanced Splenic Marginal Zone Lymphoma,” Pathology and Oncology Research, Vol. 13, No. 4, 2007, pp. 382-384.

[8]   G. E. Gurvits, R. Mahtani and I. Halperin, “Hepatitis C Virus and Splenic Marginal Zone Lymphoma with Villous Lymphocytes: Away from Conventional Therapy,” Scandinavian Journal of Gastroenterology, Vol. 42, No. 11, 2007, pp. 1392-1393.

[9]   J. Svoboda, C. Andreadis, L. H. Downs, W. T. Miller Jr., D. E. Tsai and S. J. Schuster, “Regression of Advanced Non-Splenic Marginal Zone Lymphoma after Treatment of Hepatitis C Virus Infection,” Leuk Lymphoma, Vol. 46, No. 9, 2005, pp. 1365-1368.

[10]   L. Arcaini, S. Burcheri, A. Rossi, M. Paulli, R. Bruno, F. Passamonti, et al., “Prevalence of HCV Infection in Non-gastric Marginal Zone B-Cell Lymphoma of MALT,” Annals of Oncology, Vol. 18, No. 2, 2007, pp. 346-350.

[11]   L. Christou, G. Kalambokis, M. Bai, S. Kamina and E. V. Tsianos, “Splenic Marginal Zone Lymphoma in a Patient with Chronic Hepatitis B,” Journal of Gastrointestinal and Liver Diseases, Vol. 18, No. 4, 2009, pp. 511-512.

[12]   E. Gómez-de la Fuente, L. B. Villalón, L. Calzado-Villarreal, F. Pinedo-Moraleda and J. L. López-Estebaranz, “Splenic Marginal Zone B-Cell Lymphoma with Epidermotropic Skin Involvement,” Actas Dermosifiliogr, Vol. 103, No. 5, 2012, pp. 427-431.

[13]   S. H. Zhang, A. M. Xu, J. M. Zheng and M. X. He, “Coexistence of Splenic Marginal Zone Lymphoma with Hepatocellular Carcinoma: A Case Report,” Diagnostic Pathology, Vol. 2, 2007, p. 5.

[14]   K. Fujimoto, T. Endo, M. Nishio, M. Obara, K. Yamaguchi, Y. Takeda, et al., “Complete Remission of Splenic Marginal Zone Lymphoma after an Acute Flare-Up of Hepatitis B in a Hepatitis B Virus Carrier,” International Journal of Hematology, Vol. 90, No. 5, 2009, pp. 601-604.

[15]   S. Kusumoto, Y. Tanaka, R. Ueda and M. Mizokami, “Reactivation of Hepatitis B Virus Following Rituximab-Plus-Steroid Combination Chemotherapy,” Journal of Gastroenterology, Vol. 46, No. 1, 2011, pp. 9-16.

[16]   S. Kusumoto, Y. Tanaka, M. Mizokami and R. Ueda, “Clinical Significance of Hepatitis B Virus (HBV)-DNA Monitoring to Detect HBV Reactivation after Systemic Chemotherapy,” Journal of Clinical Oncology, Vol. 29, No. 4, 2011, p. e100.

[17]   C. Kalpadakis, G. A. Pangalis, M. N. Dimopoulou, T. P. Vassilakopoulos, M. C. Kyrtsonis, P. Korkolopoulou, et al., “Rituximab Monotherapy Is Highly Effective in Splenic Marginal Zone Lymphoma,” Hematological Oncology, Vol. 25, No. 3, 2007, pp. 127-131.

[18]   E. Zucca, A. Conconi, D. Laszlo, A. López-Guillermo, R. Bouabdallah, B. Coiffier, et al., “Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients with Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study,” Journal of Clinical Oncology, Vol. 31, No. 5, 2013, pp. 565-572.